Skip to main content

Table 1 Patient demographics

From: CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin

  CBR3 Genotype   
AA AG GG All Patients p Valve
(N = 13) (N = 53) (N = 26) (N = 92)
n (%) n (%) n (%) n (%)
Chemotherapy, mean ± SD
 Anthracycline dose, mg 461 ± 77 424 ± 60 439 ± 49 433 ± 61 0.168
 Cytoxan dose, mg 4645 ± 827 4315 ± 579 4397 ± 517 4384 ± 615 0.979
 Treatment days 4 ± 0 3.9 ± 0.37 4.0 ± 0.19 3.9 ± 0.4 0.2849
Trastuzumab (adjuvant) 1 (8%) 4 (8%) 3 (11%) 8 (9%) 0.859
Chest radiation, left-side 6 (46%) 28 (53%) 12 (46%) 46 (50%) 0.732
Sex, female 11 (85%) 53 (100%) 26 (100%) 90 (98%) 0.002*
Age, years
 Mean ± SD 55 ± 12 51 ± 12 51 ± 12 52 ± 11 0.692
 Range 33–76 24–73 32–73 24–76  
Race
 Caucasian 10 (77%) 48 (91%) 23 (89%) 81 (88%) 0.396
 African American 1 (8%) 4 (8%) 3 (11%) 8 (9%)  
 Hispanic 0 0 0 0  
 Asian 1 (8%) 0 0 1 (1%)  
 Mixed 1 (8%) 1 (2%) 0 2 (2%)  
Comorbidities
 Hypertension 5 (38%) 15 (28%) 5 (19%) 25 (27%) 0.386
 Diabetes 1 (8%) 3 (6%) 2 (7%) 6 (6%) 0.938
 Hyperlipidemia 6 (46%) 9 (17%) 5 (19%) 21 (23%) 0.069
 Smoking history 4 (31%) 21 (40%) 10 (37%) 35 (38%) 0.838
Medication
 ACE inhibitor 1 (8%) 5 (9%) 3 (11%) 9 (10%) 0.126
 ARB 2 (15%) 3 (6%) 2 (7%) 7 (8%) 0.492
 Beta blocker 2 (15%) 4 (8%) 1 (4%) 7 (8%) 0.423
 Statin 4 (31%) 6 (11%) 0 (0%) 10 (11%) 0.014*
  1. Differences between groups were compared using Fisher’s exact for categorical variables and one-way ANOVA for continuous variables
  2. *p < 0.05, indicates significant differences between subgroups
  3. Abbreviations: SD standard deviation, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker